Julieta Haydee Sepulveda

Mrs. Julieta Haydee Sepulveda

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
MGMontserrat Goles
Montserrat Goles
ADAnamaria C Daza-Sanchez
Anamaria C Daza-Sanchez
GCGabriel Cabas-Mora
Gabriel Cabas-Mora
LSLindybeth Sarmiento-Varón
Lindybeth Sarmiento-Varón
JSJulieta Haydee Sepulveda
Julieta Haydee Sepulveda
DMDavid Medina-Ortiz
David Medina-Ortiz
With their diverse biological activities, peptides are promising candidates for therapeutic applications, showing antimicrobial, antitumour and hormonal signalling capabilities. Despite their advantages, therapeutic peptides face challenges such as short half-life, limited oral bioavailability and susceptibility to plasma degradation. The rise of computational tools and artificial intelligence (AI) in peptide research has spurred the development of advanced methodologies and databases that are pivotal in the exploration of these complex macromolecules. This perspective delves into integrating AI in peptide development, encompassing classifier methods, predictive systems and the avant-garde design facilitated by deep-generative models like generative adversarial networks and variational autoencoders. There are still challenges, such as the need for processing optimization and careful validation of predictive models. This work outlines traditional strategies for machine learning model construction and training techniques and proposes a comprehensive AI-assisted peptide design and validation pipeline. The evolving landscape of peptide design using AI is emphasized, showcasing the practicality of these methods in expediting the development and discovery of novel peptides within the context of peptide-based drug discovery.

8 November 2024 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
GCGabriel Cabas-Mora
Gabriel Cabas-Mora
ADAnamaria C Daza-Sanchez
Anamaria C Daza-Sanchez
NSNicole Soto-Garcia
Nicole Soto-Garcia
VGValentina Garrido
Valentina Garrido
DADiego Alvarez
Diego Alvarez
DMDavid Medina-Ortiz
David Medina-Ortiz
In recent years, peptides have gained significant relevance due to their therapeutic properties. The surge in peptide production and synthesis has generated vast amounts of data, enabling the creation of comprehensive databases and information repositories. Advances in sequencing techniques and artificial intelligence have further accelerated the design of tailor-made peptides. However, leveraging these techniques requires versatile and continuously updated storage systems, along with tools that facilitate peptide research and the implementation of machine learning for predictive systems. This work introduces Peptipedia v2.0, one of the most comprehensive public repositories of peptides, supporting biotechnological research by simplifying peptide study and annotation. Peptipedia v2.0 has expanded its collection by over 45% with peptide sequences that have reported biological activities. The functional biological activity tree has been revised and enhanced, incorporating new categories such as cosmetic and dermatological activities, molecular binding, and antiageing properties. Utilizing protein language models and machine learning, more than 90 binary classification models have been trained, validated, and incorporated into Peptipedia v2.0. These models exhibit average sensitivities and specificities of 0.877±0.0530 and 0.873±0.054, respectively, facilitating the annotation of more than 3.6 million peptide sequences with unknown biological activities, also registered in Peptipedia v2.0. Additionally, Peptipedia v2.0 introduces description tools based on structural and ontological properties and user-friendly machine learning tools to facilitate the application of machine learning strategies to study peptide sequences. Database URL: https://peptipedia.cl/

2 March 2021 in Blood
Verified
Journal Article
Closed access
PDF file
PMPablo Elías Morande
Pablo Elías Morande
XYXiao-Jie Yan
Xiao-Jie Yan
JSJulieta Haydee Sepulveda
Julieta Haydee Sepulveda
NSNoé Seija
Noé Seija
MMMaría Elena Marquez
María Elena Marquez
POPablo Oppezzo
Pablo Oppezzo
Most cancers become more dangerous by the outgrowth of malignant subclones with additional DNA mutations that favor proliferation or survival. Using chronic lymphocytic leukemia (CLL), a disease exemplary of this process, and a model for neoplasms in general, we created transgenic mice overexpressing the enzyme, activation-induced deaminase (AID), whose normal function is to induce DNA mutations in B lymphocytes. AID allows normal B lymphocytes to develop more effective immunoglobulin (Ig)-mediated immunity, but also is able to mutate non-Ig genes, predisposing to cancer. In chronic lymphocytic leukemia (CLL), AID expression correlates with poor prognosis suggesting a role for this enzyme in disease progression. Nevertheless, direct experimental evidence identifying the specific genes that are mutated by AID and indicating that those genes are associated with disease progression is not available. To address this point, we overexpressed Aicda in a murine model of CLL (Em-TCL1). Analyses of TCL1/AID mice demonstrate a role for AID in disease kinetics, CLL-cell proliferation, and the development of cancer-related target mutations with canonical AID signatures in non-Igs genes. Notably, our mouse models can accumulate mutations in the same genes that are mutated in human cancers. Moreover, some of these mutations occur at homologous positions, leading to identical or chemically-similar amino acid substitutions as in human CLL and lymphoma.Together, these findings support a direct link between aberrant AID activity and CLL driver mutations that are then selected for their oncogenic effects, whereby AID promotes aggressiveness in CLL and other B-cell neoplasms.

21 March 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JEJanneke A. Eken
Janneke A. Eken
MKMarvyn T. Koning
Marvyn T. Koning
KKKristyna Kupcova
Kristyna Kupcova
JSJulieta Haydee Sepulveda
Julieta Haydee Sepulveda
RGRuben de Groen
Ruben de Groen
HVHendrik Veelken
Hendrik Veelken
Diffuse large B cell lymphoma of activated B cell type (ABC-DLBCL), a major cell-of-origin DLBCL subtype, is characterized by chronic active B cell receptor (BCR) signaling and NF-κB activation, which can be explained by activating mutations of the BCR signaling cascade in a minority of cases. We demonstrate that autonomous BCR signaling, akin to its essential pathogenetic role in chronic lymphocytic leukemia (CLL), can explain chronic active BCR signaling in ABC-DLBCL. 13 of 18 tested DLBCL-derived BCR, including 12 cases selected for expression of IgM, induced spontaneous calcium flux and increased phosphorylation of the BCR signaling cascade in murine triple knockout pre-B cells without antigenic stimulation or external BCR crosslinking. Autonomous BCR signaling was associated with IgM isotype, dependent on somatic BCR mutations and individual HCDR3 sequences, and largely restricted to non-GCB DLBCL. Autonomous BCR signaling represents a novel immunological oncogenic driver mechanism in DLBCL originating from individual BCR sequences and adds a new dimension to currently proposed genetics- and transcriptomics-based DLBCL classifications.

24 March 2021 in Genome Medicine
Verified
Journal Article
Open access
PDF file
SSShadi Darvish Shafighi
Shadi Darvish Shafighi
SKSzymon M. Kiełbasa
Szymon M. Kiełbasa
JSJulieta Haydee Sepulveda
Julieta Haydee Sepulveda
RMRamin Monajemi
Ramin Monajemi
DCDavy Cats
Davy Cats
ESEwa Szczurek
Ewa Szczurek
Background: Drawing genotype-to-phenotype maps in tumors is of paramount importance for understanding tumor heterogeneity. Assignment of single cells to their tumor clones of origin can be approached by matching the genotypes of the clones to the mutations found in RNA sequencing of the cells. The confidence of the cell-to-clone mapping can be increased by accounting for additional measurements. Follicular lymphoma, a malignancy of mature B cells that continuously acquire mutations in parallel in the exome and in B cell receptor loci, presents a unique opportunity to join exome-derived mutations with B cell receptor sequences as independent sources of evidence for clonal evolution. Methods: Here, we propose CACTUS, a probabilistic model that leverages the information from an independent genomic clustering of cells and exploits the scarce single cell RNA sequencing data to map single cells to given imperfect genotypes of tumor clones. Results: We apply CACTUS to two follicular lymphoma patient samples, integrating three measurements: whole exome, single-cell RNA, and B cell receptor sequencing. CACTUS outperforms a predecessor model by confidently assigning cells and B cell receptor-based clusters to the tumor clones. Conclusions: The integration of independent measurements increases model certainty and is the key to improving model performance in the challenging task of charting the genotype-to-phenotype maps in tumors. CACTUS opens the avenue to study the functional implications of tumor heterogeneity, and origins of resistance to targeted therapies. CACTUS is written in R and source code, along with all supporting files, are available on GitHub (https://github.com/LUMC/CACTUS).

29 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CBCornelis A.M. Van Bergen
Cornelis A.M. Van Bergen
SKSusan L. Kloet
Susan L. Kloet
EQEdwin Quinten
Edwin Quinten
JSJulieta Haydee Sepulveda
Julieta Haydee Sepulveda
RMRoberta Menafra
Roberta Menafra
HVHendrik Veelken
Hendrik Veelken